Drug intelligence / Profile preview

otilonium

Development stage
Phase 4
Lead developer
Menarini
Modality
Small Molecules
Administration
Oral
01

Overview

Otilonium (commonly used as the bromide salt, otilonium bromide) is a small molecule antispasmodic drug primarily indicated for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. It acts locally in the gut due to minimal systemic absorption and accumulates in the colonic wall. Otilonium exerts its effects by blocking voltage-dependent calcium channels (mainly L-type and also T-type), interfering with both intra- and extracellular calcium movement necessary for smooth muscle contraction. Additionally, it binds to muscarinic receptors and tachykinin neurokinin-2 receptors on smooth muscle cells and primary afferent neurons. These combined actions reduce abnormal gut motility, abdominal spasms, pain, bloating, and discomfort associated with IBS[1][3][4][5][6].

Brand names
Spasmoctyl 40Spasmoctyl40Spasmoctyl-40DoralinMenoctylSpasmomen
Other names
otilonium bromide
02

Targets

CHRM2 (M2)CaV3 (Caveolin-3)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)TACR2 (Neurokinin-2 Receptor)

Beyond the preview

Go deeper on otilonium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on otilonium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call